Retatrutide
aka Retatrutide (LY3437943 — GLP-1/GIP/Glucagon triple agonist)
GLP-1 / Metabolic
Mechanism
Retatrutide (Eli Lilly code LY3437943) is an investigational triple-receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. It is research-only and NOT FDA-approved as of April 2026; the Phase 3 TRIUMPH program is ongoing with anticipated NDA filing in 2026. Published Phase 2 data showed roughly 24% mean body weight loss at 48 weeks on 12 mg weekly (Jastreboff, NEJM 2023).
Identification
Vendors selling Retatrutide
No vendor listings on file yet.
Research
No citations on file yet.